Answers are grounded in this paper and cite their sources.
Our study supports the use of IPC as the primary thromboembolic prophylaxis measure in ICH patients. Further research, including head-to-head RCTs, is needed to strengthen the evidence base and optimize clinical decision-making for thromboembolic prophylaxis in this vulnerable patient population.
No takes yet. Share an insight, caveat, or question.
Maraziti et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: